Exploring the immunomodulatory factors expressed by CML-MSC at Time 0, we found a significant up-regulation of COX2, TGFβ, and IL6 compared to HD-MSC, with a great variability among patients. This evidence concerns the gene PTGS2 and chronic myelogenous leukemia, BCR-ABL1 positive.